Johnson & Johnson (JNJ)
| Market Cap | 375.64B |
| Revenue (ttm) | 89.33B |
| Net Income (ttm) | 21.81B |
| Shares Out | 2.41B |
| EPS (ttm) | 8.98 |
| PE Ratio | 17.38 |
| Forward PE | 14.81 |
| Dividend | $5.20 (3.33%) |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 5,973,906 |
| Open | 155.70 |
| Previous Close | 154.46 |
| Day's Range | 155.10 - 156.70 |
| 52-Week Range | 140.68 - 169.99 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 170.40 (+9.15%) |
| Earnings Date | Apr 15, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $170.4, which is an increase of 9.15% from the latest price.
News
Dogs Of The Dow Chase May's 'Safer' Buy
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding the single share price, supported by adequate free cash flow. Analyst projections suggest top Dow Dogs cou...
Calls of the Day: AutoZone, Roblox, Eli Lilly, Johnson & Johnson and Quanta Services
Oppenheimer upgrades AutoZone — NewEdge Wealth CEO Rob Sechan owns it and breaks it down, while the Investment Committee drops their latest picks.
J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports
HistoSonics, a medical technology company backed by Johnson & Johnson , is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing peopl...
FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. First and only FcRn blocker approved in anti-AChR and anti-MuSK a...
US FDA approves J&J's immune disorder drug
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobul...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Trump to tout US investments from Nvidia, J&J, Hyundai, Toyota
CEOs and other executives from Nvidia , Johnson & Johnson , Toyota Motor , Eli Lilly and SoftBank Group are among the more than two-dozen senior business leaders slated to visit the White House on Wed...
My 10 Must-Own Dividend Stocks For Your Retirement Portfolio (One Yields 9.65%)
I present 10 must-own dividend stocks for your retirement portfolio to help you blend dividend income, growth and capital appreciation, designed to anchor a well-diversified dividend portfolio. Allian...
Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate...
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avo...
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potential...
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease
The first a approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis, 1 , 2 , 3 , 4 , 5 guselkumab showed statistically higher rates of en...
Johnson & Johnson Just Proved The Bears Wrong Again
Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. It beat the consensus estimates again by a wide margin, thanks to its leading positions in the oncology...
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising...
Two Stocks To Consider During Market Unrest To Provide Income Stability
Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price st...
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study...
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Johnson & Johnson: 15% of AI Use Cases Deliver 80% of Value
Johnson & Johnson reportedly found that 10% to 15% of artificial intelligence use cases deliver 80% of the value.
Johnson & Johnson Pivots Its AI Strategy
The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or underdelivering.
Why Most Dividend Retirement Strategies Fail: How To Retire With Dividends
Most high-yield strategies are ticking time bombs. Don't get wiped out when the next downturn hits. Discover the only portfolio blend that can deliver sustainable and rising dividends through inflatio...
Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a...